← Who reports today · Health Care
Bristol Myers Squibb (BMY) earnings date & Q3 2026 results
Net Earnings/(Loss) Attributable to BMS
$2,162M
down 1.8% y/y
Total Revenues
$13,069M
up 6.9% y/y
Next report
~ Feb 4
not announced yet
The quarter in brief
GAAP net income attributable to BMS was $2,162 million, or $1.05 diluted per share, versus $2,201 million, or $1.08, a year earlier.
Key growth driver: Net product sales — the fastest-growing revenue line: $12,606, +6% y/y. · by the Q3 2026 report
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net product sales | $12,606 · +6.4% |
| Alliance and other revenues | $463 · +24.5% |
| Total Revenues | $13,069 · +6.9% |
| Cost of products sold | $4,146 · +20.7% |
| Selling, general and administrative | $1,699 · −5.0% |
| Research and development | $2,365 · −6.4% |
| Acquired IPRD | $1,558 · +146% |
| Amortization of acquired intangible assets | $458 · −44.9% |
| Other (income)/expense, net | $307 · vs −$108 |
| Earnings/(Loss) Before Income Taxes | $2,536 · −18.6% · 19.4% margin |
| Income tax provision | $374 · −59.3% · 14.7% effective rate |
| Net Earnings/(Loss) Attributable to BMS | $2,162 · −1.8% · $1.05/sh · 16.5% margin |
Verdict: GAAP net income attributable to BMS was $2,162 million, or $1.05 diluted per share, versus $2,201 million, or $1.08, a year earlier.
Total revenues were $13,069 million versus $12,222 million, and GAAP earnings before income taxes were $2,536 million versus $3,114 million a year ago.
Source and notation
Source: Bristol Myers Squibb earnings release, 8-K EX-99 of 10/29/2026 (SEC EDGAR).
Open as an image: Bristol Myers Squibb (BMY), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Bristol Myers Squibb (BMY) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/bmy. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/bmy"><img src="https://whoreportstoday.com/t/bmy/img/bristol-myers-squibb-bmy-earnings-sankey.png" alt="Bristol Myers Squibb (BMY) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/bmy">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/bmy/img/bristol-myers-squibb-bmy-earnings-sankey.png
<a href="https://whoreportstoday.com/t/bmy">Bristol Myers Squibb (BMY) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- GAAP gross margin decreased from 71.9% to 68.3%; cost of products sold rose to $4,146 million from $3,435 million.
- GAAP effective tax rate fell to 14.8% from 29.5%, with income tax provision of $374 million versus $919 million.
- SG&A expenses were $1,699 million versus $1,789 million, and R&D expenses were $2,365 million versus $2,528 million.
- Acquired IPRD charges rose to $1,558 million from $633 million.
- Amortization of acquired intangible assets was $458 million, down from $831 million.
- Other (income)/expense, net was an expense of $307 million versus income of $108 million a year ago.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Christopher BoernerChair of the Board and Chief Executive Officer [1]
- David V. ElkinsChief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Bristol-Myers Squibbsince 2015
- Chair of the Board and Chief Executive Officersince 2024
- Chief Executive Officer2023–2024
- Executive Vice President, Chief Operating Officer2023
- Executive Vice President, Chief Commercialization Officer2018–2023
- President and Head, International Markets2017–2018
- President and Head of U.S. Commercial2015–2017
Source: SEC EDGAR: 10-K annual report, 2026-02-11 · as of 10/21/2026
- Bristol-Myers Squibbsince 2019Executive Vice President and Chief Financial Officer
- Celgene2018–2019Chief Financial Officer
- Johnson & Johnson2014–2018
- Worldwide Vice President and Chief Financial Officer, Consumer Products, Medical Development and Corporate Functions2017–2018
- Group Vice President and Chief Financial Officer, Consumer and Consumer Medicines2014–2017
Source: SEC EDGAR: 10-K annual report, 2026-02-11 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-10-29 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-10-29 · SEC EDGAR · 11/18/2026
Bristol Myers Squibb — Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. · Text: Wikipedia, CC BY-SA 4.0, abridged
The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. Market share (US pharma & biotech): ≈7% by TTM revenue.
Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | revenue $49.75–50.25B (raised)EPS (non-GAAP) $6.35–6.55 (raised) | revenue $48.2BEPS (GAAP) $3.46 | revenue +3…4% |
Same quarter a year ago (ended December 31, 2025): revenue $12.5B, EPS (GAAP) $0.54
How we calculate
Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +4%).
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 29, 2026); every figure is checked against the release text.
BMY earnings history: past report dates
| Oct 29, 2026 Thu | 7:05 ambefore market open | Sep 30, 2026 | $13.1B+7% y/y | $1.05−3% y/y |
| Jul 30, 2026 Thu | 7:05 ambefore market open | Jun 30, 2026 | $13.0B+6% y/y | $1.62+153% y/y |
| Apr 30, 2026 Thu | 7:01 ambefore market open | Mar 31, 2026 | $11.5B+3% y/y | $1.31+9% y/y |
| Feb 5, 2026 Thu | 7:07 ambefore market open | Dec 31, 2025 | ≈$12.5B+1% y/y | ≈$0.54+980% y/y |
| Oct 30, 2025 Thu | 7:09 ambefore market open | Sep 30, 2025 | $12.2B+3% y/y | $1.08+80% y/y |
| Jul 31, 2025 Thu | 7:06 ambefore market open | Jun 30, 2025 | $12.3B+1% y/y | $0.64−23% y/y |
| Apr 24, 2025 Thu | 7:11 ambefore market open | Mar 31, 2025 | $11.2B−6% y/y | $1.20 |
| Feb 6, 2025 Thu | 7:46 ambefore market open | Dec 31, 2024 | ≈$12.3B+8% y/y | ≈$0.05−94% y/y |
| Oct 31, 2024 Thu | 7:52 ambefore market open | Sep 30, 2024 | $11.9B+8% y/y | $0.60−35% y/y |
| Jul 26, 2024 Fri | 7:46 ambefore market open | Jun 30, 2024 | $12.2B+9% y/y | $0.83−16% y/y |
| Apr 25, 2024 Thu | 7:47 ambefore market open | Mar 31, 2024 | $11.9B+5% y/y | −$5.89 |
| Feb 2, 2024 Fri | 7:46 ambefore market open | Dec 31, 2023 | ≈$11.5B+1% y/y | ≈$0.87−8% y/y |
| Oct 26, 2023 Thu | 7:44 ambefore market open | Sep 30, 2023 | $11.0B−2% y/y | $0.93+24% y/y |
| Jul 27, 2023 Thu | 7:50 ambefore market open | Jun 30, 2023 | $11.2B−6% y/y | $0.99+50% y/y |
| Apr 27, 2023 Thu | 7:45 ambefore market open | Mar 31, 2023 | $11.3B−3% y/y | $1.07+81% y/y |
| Feb 2, 2023 Thu | 8:43 ambefore market open | Dec 31, 2022 | ≈$11.4B−5% y/y | ≈$0.95−11% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Bristol Myers Squibb: 15-year financials
| 2025 | 48,194 | 7,054 | 12,845 | 5,045 |
| 2024 | 48,300 | −8,948 | 13,942 | 4,863 |
| 2023 | 45,006 | 8,025 | 12,651 | 4,744 |
| 2022 | 46,159 | 6,327 | 11,948 | 4,634 |
| 2021 | 46,385 | 6,994 | 15,234 | 4,396 |
| 2020 | 42,518 | −9,015 | 13,299 | 4,075 |
| 2019 | 26,145 | 3,439 | 7,374 | 2,679 |
| 2018 | 22,561 | 4,920 | 6,115 | 2,613 |
| 2017 | 20,776 | 1,007 | 4,220 | 2,577 |
| 2016 | 19,427 | 4,457 | 1,843 | 2,547 |
| 2015 | 16,560 | 1,565 | 1,285 | 2,477 |
| 2014 | 15,879 | 2,004 | 2,622 | 2,398 |
| 2013 | 16,385 | 2,563 | 3,008 | 2,309 |
| 2012 | 17,621 | 1,960 | 6,393 | 2,286 |
| 2011 | 21,244 | 3,709 | 4,473 | 2,254 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Bristol Myers Squibb: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 90,038 | 18,473 | 47,088 | 10,209 | 29,390 | 23,417 |
| 2024 | 92,603 | 16,335 | 51,477 | 10,346 | 29,780 | 23,774 |
| 2023 | 95,159 | 29,430 | 42,645 | 11,464 | 31,770 | 22,262 |
| 2022 | 96,820 | 31,061 | 43,217 | 9,123 | 27,273 | 21,890 |
| 2021 | 109,314 | 35,946 | 49,317 | 13,979 | 33,262 | 21,868 |
| 2020 | 118,481 | 37,822 | 52,676 | 14,546 | 30,192 | 19,080 |
| 2019 | 129,944 | 51,598 | 49,496 | 12,346 | 29,354 | 18,304 |
| 2018 | 34,986 | 14,031 | 8,598 | 6,911 | 17,716 | 10,654 |
| 2017 | 33,551 | 11,741 | 7,962 | 5,421 | 14,854 | 9,563 |
| 2016 | 33,707 | 16,177 | 6,574 | 4,237 | 13,704 | 8,841 |
| 2015 | 31,748 | 14,266 | 6,828 | 2,385 | 10,415 | 8,017 |
| 2014 | 33,749 | 14,852 | 8,422 | 5,571 | 14,608 | 8,461 |
| 2013 | 38,592 | 15,154 | 8,340 | 3,586 | 18,916 | 12,440 |
| 2012 | 35,897 | 13,623 | 8,058 | 1,656 | 9,521 | 8,279 |
| 2011 | 32,970 | 15,956 | 5,491 | 5,776 | 15,318 | 7,780 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 8,678 | 12,182 | −3,504 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 1,814 | 3,034 | |
| · incl. stock-based comp (non-cash)share-based compensation | 419 | 420 | |
| Capexpurchases of property & equipment | −996 | −941 | −55 |
| Free cash flow ≈operating cash flow − capex | 7,682 | 11,241 | −3,559 |
| Investing activities, netcapex, acquisitions, securities | −3,849 | −2,674 | −1,175 |
| · incl. acquisitionsbusinesses net of cash acquired | −1,268 | −2,237 | +969 |
| Financing activities, netdebt, buybacks, dividends | −5,412 | −4,319 | −1,093 |
| · incl. dividends paid | −3,857 | −3,783 | −74 |
| FX effect on cash | −61 | 190 | −251 |
| Net change in cash | −644 | 5,379 | −6,023 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: $23.4B (26% of total assets). Compare with other S&P 500 companies →
Corporate governance
1.5/2mostly good
- Feb 202610-K FY2025: in September 2025 the parties reached a settlement of the Celgene shareholder class action (purchasers from Apr 2017 to Apr 2018); the court granted preliminary approval in Dec 2025. sec.gov ↗
- May 2026The court granted final approval to a $239M settlement of the suit by former Celgene shareholders over overstated prospects for Otezla and Zeposia. news.bloomberglaw.com ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Feb 2026Dividend per share $1.84 (2020) → $2.49 (2025), raised every year; diluted shares −9.7% over 5 years. data.sec.gov ↗
Scoring: 2.0 −0.5 (criterion 9: $239M settlement of the former Celgene shareholders' suit, approved by the court in May 2026) = 1.5
- Share classes
- Single class of common stock; the Celgene CVR is a separate non-voting security.
- Dilution
- Diluted shares 2,258M (2020) → 2,039M (2025), −9.7%; SBC 1.1% of revenue; the all-stock Celgene acquisition was in 2019, outside the 5-year window.
- Disclosure
- Full reporting.
- Dividends
- Dividend raised every year: $1.84 (2020) → $2.49 (2025); buybacks of $5–8B in 2021–2023.
- Lawsuits & regulators
- Celgene suit (2018) settled for $239M, approved May 2026 → −0.5; CVR holders' suits unresolved → no deduction; the 2004 SEC case and the 2002–2004 shareholder suit are older than 15 years and not counted.
- Related parties
- Related-party transactions limited to routine BlackRock/Vanguard/JPM services on market terms (2026 proxy).
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Bristol Myers Squibb (BMY) earnings: FAQ
When is BMY's next earnings date?
We have not yet seen an announcement of the date from Bristol Myers Squibb (BMY). Based on last year's report on Feb 5, 2026, the next report is expected around Feb 4, 2027.
What time does BMY report earnings?
Bristol Myers Squibb usually reports before market open: its latest results release was filed with the SEC at 7:05 am ET on Oct 29, 2026.
When did BMY last report earnings?
Bristol Myers Squibb reported Q3 2026 results on Oct 29, 2026.
What has Bristol Myers Squibb guided for FY2026?
Company guidance for FY2026: revenue $49.75–50.25B (raised); EPS (non-GAAP) $6.35–6.55 (raised). A year ago (FY2025): revenue $48.2B, EPS (GAAP) $3.46. Implied growth: revenue +3…4%. Source: the company's earnings release (Form 8-K filed Oct 29, 2026).
Where can I find Bristol Myers Squibb's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to BMY's filings; this page breaks the latest report down in a Sankey chart.
What was BMY's net income in Q3 2026?
Bristol Myers Squibb reported net income of $2,162M for Q3 2026 (−1.8% year over year), under US GAAP.
Does Bristol Myers Squibb pay dividends?
Yes. In 2025, Bristol Myers Squibb paid $5,045M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Bristol Myers Squibb's revenue changed since 2011?
Per its 10-K filings, revenue grew 2.3x: $21,244M in 2011 and $48,194M in 2025. The peak was $48,300M in 2024. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · CNC · Q3 2026 · COO · Q3 FY2026 · COR · Q4 FY2026 · CRL · Q3 2026 · CVS · Q3 2026 · DGX · Q3 2026 · DHR · Q3 2026 · all reports